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INTRODUCTION
Unsafe abortion is prevalent in many developing
countries where abortion laws are more restrictive, the
unmet need for contraception is high, and the status
of women in society is low. The main interventions
for reducing the prevalence of unsafe abortion are
known: better and more widely available family plan-
ning services, comprehensive sex education, higher
access to safe abortion and high-quality post-abortion
care, including contraceptive counselling and on-site
services.1
According to the WHO, 19 million women have
illegal abortion every year and 18.5 million of these
take place in developing countries.2 The number of
mortality due to illegal abortion was estimated to be
around 68.000 deaths annually.3 Medical methods of-
fer safer alternative way compared to operative pro-
cedure.4
Abstract
Objective: To evaluate the efficacy and adverse effect of miso-
prostol in pregnancy termination under 22 weeks of gestation with
dosage 400 μg, in comparison to 600 μg.
Method: The research was performed in Obstetric and Gyneco-
logy Division in Dr. Cipto Mangunkusumo General Hospital to 70
subjects which were chosen with consecutive sampling, divided into
two groups with block randomization and double blind. Group A re-
ceived 400 μg of misoprostol every 6 hours while group B received
600 μg of misoprostol every 6 hours for a maximum of 2 days. Each
group was evaluated for the time it took to reach complete abortion
and for the adverse effects, consisting of abdominal cramping,
bleeding, vomiting, and diarrhea.
Result: Success rate for termination with misoprostol 400 μg
and 600 μg were 88.5% and 91.4%, with no statistical difference
found (p=1.000). There was no difference in the time for reaching
complete abortion between two dosages (p=0.701) with a mean of
22 ± 8 hours. Adverse effects were found more frequent and more
severe in the group consuming 600 μg of misoprostol compared to
the group receiving 400 μg of misoprostol.
Conclusion: Four hundred micrograms of misoprostol every six
hour is recommended for termination of pregnancy under 22 weeks
of gestational age, without statistical difference in efficacy, but with
lower adverse effects.
[Indones J Obstet Gynecol 2010; 34-2: 59-63]
Keywords: misoprostol, pregnancy failure, dosage, efficacy, ad-
verse effect
Abstrak
Tujuan: Mengetahui efektivitas dan efek samping penggunaan
misoprostol 400 μg dibandingkan dengan misoprostol 6oo μg untuk
pengeluaran hasil konsepsi pada kegagalan kehamilan usia ≤ 22
minggu.
Metode: Penelitian dilakukan di Departemen Obstetri dan Gi-
nekologi RSCM terhadap 70 subjek yang dipilih dengan cara pe-
ngambilan sampel berurutan lalu dibagi menjadi dua kelompok per-
lakuan dengan randomisasi blok dan ketersamaran ganda. Kelom-
pok A mendapatkan misoprostol 400 μg tiap 6 jam selama dan
kelompok B mendapat misoprostol 600 μg tiap 6 jam selama maksi-
mal 2 hari. Dilakukan penilaian lama terjadinya ekspulsi jaringan
komplit dan efek samping berupa perdarahan, kram, muntah dan
diare pada masing-masing subjek penelitian.
Hasil: Didapatkan angka keberhasilan untuk terminasi dengan
misoprostol 400 μg dan misoprostol 600 μg adalah 88,5% dan
91,4% untuk usia kehamilan ≤ 22 minggu. Tidak didapatkan perbe-
daan keberhasilan yang bermakna secara statistik (p=1,000). Tidak
didapatkan perbedaan waktu ekspulsi komplit antara kedua dosis
(p=0,701) dengan rerata waktu tercapai ekspulsi 22 ± 8 jam. Dida-
patkan perbedaan bermakna pada beratnya efek samping berupa
kram, perdarahan, muntah dan diare antara dosis 400 μg diban-
dingkan dengan dosis 600 μg, di mana efek samping lebih sering di-
dapatkan dan lebih berat pada kelompok perlakuan dengan dosis
600 μg.
Kesimpulan: Penggunaan misoprostol dosis 400 μmg lebih di-
sarankan untuk pengeluaran hasil konsepsi pada kegagalan keha-
milan usia ≤ 22 minggu dibandingkan dengan dosis 600 μg dengan
efektivitas yang tidak berbeda bermakna namun efek samping yang
ditimbulkan lebih sedikit.
[Maj Obstet Ginekol Indones 2010; 34-2: 59-63]
Kata kunci: misoprostol, kegagalan kehamilan, dosis, efektivi-
tas, efek samping
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Medical abortion is a method for pregnancy termi-
nation using single – or combination – dose of oral
administered drugs, vaginal medication, and/or intra-
muscular drugs, resulting in conception-mass expul-
sion. There are three medical abortion combination
methods use worldwide. These are mifepriston and
misoprostol, methotrexate and misoprostol, and miso-
prostol only.5
Several researches have shown that medical abor-
tion is safe enough, effective, and has high acceptance
for both the patient and caregivers.5 The method using
single misoprostol can be used in many regions which
has no mifepriston available, with fine results.5,6
Nowadays, pregnancy termination is generally
done by performing either dilatation and curetation.
Meanwhile, the absolute regimen in pregnancy termi-
nation using medical method is not yet to be disco-
vered. In literature, using 600 μg of isoprostol trough
buccal mucous in less than 12 weeks of pregnancy
has a success rate of 86%.5-7 There is no established
recommendation for termination of pregnancy in 13
-22 weeks using oral misoprostol. Higher dosage is
needed during the administration of oral route com-
pared to other routes in order to produce similar ef-
fect. However, oral route is the most acceptable and
comfortable method for patients.
METHOD
The study was conducted after FKUI ethical commis-
sion approval had been obtained, and the samples
were collected from January to September 2009. The
method of the study was Randomized Controlled
Clinical Trial with double blind approach and parallel
independent design.
The sample was chosen with consecutive sampling.
The study population consisted of every patient which
came to our clinic with pregnancy failure. Samples
were divided into two groups with block randomiza-
tion. Group A received 600 μg misoprostol orally
every 6 hours, and group B received 400 μg miso-
prostol orally every 6 hours. Both groups fulfilled the
inclusion criteria and were willing to participate in
the research.
Sample size was calculated with hypothetical study
formula by means of two populations of independent
groups. Based on the calculation, the study required
35 people for each group.
The primary outcome measured was the expulsion
of conception mass. It was measured every 6 hours
after given misoprostol with physical examination and
transvaginal ultrasound if needed. The dose was re-
peated every 6 hours if a complete abortion has not
been achieved. A failed induction was defined as fail-
ure to expel the conception mass completely after 48
hours or heavy bleeding occurred at which point
evacuation will be done either with high dose oxyto-
cin infusion or curetage. The time interval between
induction and complete abortion were recorded.
Secondary outcome measured were misoprostol
side effects, which include vaginal bleeding, abdomi-
nal cramping, nausea/vomiting, and diarrhea. Abdo-
minal cramping were divided into 3 classes, class 1
correspond to menstrual cramping, class 2 more se-
vere than menstrual cramping but still tolerable, class
3 heavy abdominal cramping which already disturb
daily activity. Vaginal bleeding were divided into 4
classes. Class 1 spotting, class 2 correspond to men-
strual bleeding, class 3 more heavy than menstrual
bleeding, class 4 severe bleeding that cause the patient
to worry. Diarrhea were divided into 2 classes, class
1 with frequency < 5 times/day, class 2 with fre-
quency ≥ 5 times/day. Vomiting were divided into 3
classes. Class 1 benign (frequency < 5 times/day),
class 2 medium (frequency 5 - 10 times/day), and
class 3 heavy (frequency ≥ 10 times/day).
Data were analyzed using the SPSS 11.5 Statistical
analyses were performed using the Chi-square test or
Fischer exact test for qualitative variable and Kolmo-
gorov-smirnov test for ordinal and dicotomic qualita-
tive variable. p < 0.05 was considered significant.
RESULT
Sample collection was conducted from January 2009
to September 2009. Research sample consists of 35
subjects for each group.










<21 Yo  7  4
21-30 Yo 17 19 0.16 
>30 11 12
Academic Background
SD/SMP  7 11
SMA 21 17 0.519
College/Above  7  7
Occupation
Housewife 24 27 0.591
Carier Woman 11  8
Parity
Primi 17 14 0.630
Multi 18 21
Indication
BO  9  8
Conceptus
Demise 14 17
MCA  2  3 0.430
Missed/Retain
Conception  3  5
IUFD  7  2
Subject age in this research ranged from 17 - 45
years old with average age is 29 years old and most
of subjects (51.4%) are included in the group age of
21 - 30 years old. Most subject’s academic back-
ground were high school (54.2%) and most of them
were housewives (72.8%) and also most of these sub-
jects were multiparity (55.7%).
The conception demise is the leading indication for
pregnancy termination in this research, followed by
blighted ovum (44.2% and 24.2%).
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Equality review was performed on subject charac-
teristic and the indication for pregnancy termination
between group with 400 μg misoprostol and 600 μg,
whereas no significant differences were found on the
research subject (p>0.05)
Table 2. Efficacy for each research group
Misoprostal dose Succeed Fail p
400 μg 31 4 1.000
600 μg 32 3
The results showed that the use of 400 μg and 600
μg of misoprostol orally every 6 hours for pregnancy
termination below 22 weeks of gestational age, had a
high success rate (88.5% and 91.4%). No significant
differences in the success rate for termination in both
groups with p = 1.000 (fisher exact) and RR = 1.03
(0.88-1.21). (Table 2)




≤  24 Hour 24-48 Hour
400 μg 31 4 1.000
600 μg 32 3
Out of 63 subjects, the average expulsion time
needed was 22 hours ± 8 hours - with 6 hours as the
shortest expulsion time and 32 hours as the longest
period for expulsion to happen. Another finding was
that in the group of 400 μg of misoprostol, 45.1% of
subjects reached expulsion point in less than 24 hours
compared to 50% of the subjects in the group who
were given 600 μg of misoprostol. No significant dif-
ferences was found between 400 μg misoprostol and
600 μg group with p value = 0.701 and RR = 0.824
(0.306-2.217) in term of time needed for complete
expulsion. (Table 3)
Table 4. Adverse effect on both groups





Equal to menses  2  0
0.000
(KS)>Menses 32 14
Disturb daily activity  1 21
Bleeding
Equal to menses 18  3
0.003
(KS)>Menses 17 21
Causing anxiety  0 11
Vomit
None 24  3
0.003
(KS)<5 Times 11 31
5-10 Times  0  2
Diarehea
None 15  4 0,003*
<5 Times 20 31
KS: Kolmogorov-Smirnov 
*: chi square
We also found that most of the subject complained
of abdominal cramp exceeding usual menstrual period
(65.7%), but the disturbing abdominal cramping was
most likely found in the subject group of 600 μg of
misoprostol (60%) compared to the group of 400 μg
of misoprostol (2.9%).
Bleeding complaints in 400 μg misoprostol group
mostly resembled the amount of blood secreted during
menstruation (51.4) whereas the subjects in 600 μg
misoprostol group complained of bleeding in larger
amount than that in menstruation period (60%). Most
of the subjects in study group who were given 600
μg misoprostol experienced vomiting <5 times/day
(88.6%), whereas the same complaint were only found
on few patients of 400 μg misoprostol group. Diarrhea
with less than 5 times/day in the group of 400 μg
misoprostol were only found on 20 subjects (57.1%)
while in the group of 600 μg misoprostol, this com-
plaint was found on 31 subjects (88.6%) Statistical
analysis from all of the complains above found that
p-value for each of them was 0.000; 0.003; and 0.000
for cramping, bleeding, and vomiting - using the Kol-
mogorov-Smirnov calculation. For the diarrhea, the
p-value was 0.003 with Chi-Square calculation. With
p < 0.05 we concluded that there was a significant
difference for the side effects between both groups, in
which the side effects in group with 600 mg of miso-
prostol were heavier than that of the 400 mg group.
(Table 4)
DISCUSSION
The main purpose of this study was to figure out the
efficacy and to compare the adverse effects on giving
400 μg misoprostol and 600 μg orally in order to ter-
minate failed pregnancy below 22 weeks of gesta-
tional age. Seventy-women were randomly-chosen as
subject with different socio-demographic background.
Patients were dominantly regular housewives and
had already been pregnant prior to this research. Sta-
tistical review did not find any significant difference
on subject characteristics between the 400 μg and 600
μg misoprostol groups, in which the similar pattern
of subject characteristics was found.
Parity, gestational age, and pregnancy termination
indication are factors which could affect the outcome
- back in earlier days of performing such studies as
this.5,8 Complete expulsion in multiparity is much
faster then first parity.7 Nevertheless, this conclusion
was denied by other research, pointing out that there
are no correlation found between termination outcome
and parity.9
In this study, the evaluation of gestational age, di-
agnosis, and subjective parity were not reviewed with
the termination outcome because both objects matches
the different types of study designs.
Based upon literature, medical termination success
outcomes reach a percentage of between 70-95%.5,7,10
In this research, researches managed to achieve
success point for 88.5% of the group with 400 μg
misoprostol and 91.4% of the group with 600 μg mi-
soprostol. With the significant analysis, we did not
find any meaningful differences between the efficacy
of 400 μg misoprostol and 600 μg misoprostol for less
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than 22 weeks pregnancy termination [p = 1.000 and
RR=1.03 (0.88 - 1.21)].
Period of time needed for complete evacuation of
conception mass was noted, out of 63 samples taken,
no significant differences in the time needed for com-
plete conception expulsion was shown between the
400 μg misoprostol and 600 μg misoprostol (p=0.701
and RR = 0.824 [0.306-2.217]). The average of time
elapsed of expulsion is 22 ± 8 hours.
From previous studies, it is known that the effect
of using 800 μg misoprostol on second trimester con-
tinued with 400 μg orally will result in the expulsion,
which took an average of 15.9 ± 2.3 hours.11
The difference of expulsion time was due to most
of this research subject were first trimester pregnancy
failure (54.3%) with the average gestational age 13 ±
4 weeks, while in previous study the average gesta-
tional age is 20.7 ± 2.1 weeks.
This matched the literature, which explained the
correlation between gestational age and pregnancy
termination.5,8
Meanwhile, in the studies which are using 200 μg,
400 μg, and 600 μg of isoprostol via vaginal route for
pregnancy termination in second trimester, the side
effect complaints are vomiting, diarrhea, and bleed-
ing. No extraordinary treatments were necessary for
those symptoms, only a low-dose of analgesic. Sta-
tistically, the adverse effect complaints on those who
were given 600 μg are significantly different to those
of other dosage groups.12 While 800 μg via vaginal
route followed by 400 μg misoprostol via oral route
usually results to mild complaints which can be well
tolerated by the patients.11,13,14
In this research, abdominal cramping which disturb
daily activity had happened on 21 subjects (60%) in
the group of 600 μg of misoprostol, compared to only
1 subject (2.9%) in the group receiving 400 μg of
isoprostol.
This also happened with the bleeding complaints.
In group of 600 μg of misoprostol, there were 11 sub-
jects (31.4%) who complained of bleeding which
made them uncomfortable, while in the other group,
no such complain was found. Vomit reaching 5-10
times in 24 hours was found on 2 subjects (5.6%) in
the 600 μg misoprostol group and no such complain
happen in other group.
There was also an obvious clinical difference found
for diarrhea. Thirty one subjects (88.6%) in 600 μg
of misoprostol group complained of diarrhea less than
5 times/day, whereas only 20 subjects (57.1%) in the
400 μg of misoprostol group had the same complain.
We found that not every patients complained of vom-
iting and diarrhea, 37.1% patients did not experience
vomiting and 27.1% of patients did not experience
diarrhea.
Statistical analysis was performed and similar re-
sult with previous literature was found. We found sig-
nificant differences for abdominal cramping, vaginal
bleeding, vomiting, and diarrhea for group with 600
μg of misoprostol compared to group with 400 μg of
misoprostol (p = 0.000; p = 0.003; p = 0.000; and p
= 0.003).
Previous research in the literature found that the
use of misoprostol for pregnancy termination in pa-
tients with history of caesarian section until gesta-
tional age of 24 weeks is safe.15,16
In this research we had 2 subjects with history of
caesarian section twice, and one subject with history
of caesarian section once, in their early pregnancies.
Subject with twice Caesarian Section (CS) history
were given 400 μg and 600 μg of misoprostol while
one subject with history of CS once received 600 μg
of misoprostol. All of these subjects had complete ex-
pulsion of conception mass and there was no uterine
rupture or severe side effects found. In order to figure
out the statistical difference also safety and efficacy
for misoprostol in patient with history of uterine scar,
further studies with larger group studies is needed.
CONCLUSION
Administration of 400 and 600 μg of misoprostol
orally every six hours for pregnancy termination in
less than 22 weeks of gestational age are safe and
effective.
Side effects (abdominal cramping, bleeding, vom-
iting, and diarrhea) are more prevalent in the use of
600 μg compared to 400 μg of misoprostol.
The use of 400 μg of misoprostol every 6 hours
orally are recommended for pregnancy termination in
gestational age less than 22 weeks.
Further studies with larger subject group is needed
in order to figure out the statistical difference also
safety and efficacy for misoprostol in patient with
uterine scar.
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